Compare AbbVie Inc (ABBV) vs CSX Corporation (CSX) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

CSX trades at $48.51, down 0.78% on the day, with a bullish technical outlook from moving averages but neutral oscillators. The company reported a net income margin of 21.55% for 2025, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analyst consensus is a Buy with a $46.83 price target, and the stock has seen positive news coverage highlighting operational improvements and a recent dividend declaration.

The outlook for CSX is cautiously optimistic, supported by strong profitability metrics and analyst upgrades, but tempered by declining revenue trends and high valuation multiples. Key risks include freight demand volatility and competitive pressures, while institutional sentiment remains positive with a majority of analysts recommending Buy.